

MHIL Provider Memo

Molina Healthcare of Illinois, Inc. | April 29, 2024

Updates to Molina's Pharmacy Policies, Second Quarter 2024

Molina's National Pharmacy and Therapeutics (P&T) Committee periodically reviews and updates policies to stay in compliance with current medical practice and to ensure the best outcomes for patients. The P&T Committee is comprised of Molina medical staff, including medical doctors and pharmacists, as well as external independent physicians and pharmacists from various clinical specialties.

Molina Healthcare of Illinois (Molina) is making providers aware of key updates from the second quarter 2024 meeting. These updates will be effective 30 days after this notification.

Please visit MolinaClinicalPolicy.com and Molina Clinical Policies on the [Illinois provider website](#) to access new and revised pharmacy policies.

New policies

- Wegovy (semaglutide) MNR MHI
- Agamree (vamorolone) MHI
- Amtagvi (lifileucel) MCP
- Lenmeldy (atidarsagene autotemcel) MCP
- Eohilia (budesonide oral susp) MHI
- Fabhalta (iptacopan) MHI
- Filsuvez (birch triterpenes gel) MHI
- iDose TR (travoprost intracameral implant) MHI
- Rivfloza (nedosiran) MHI
- Wainua (eplontersen) MHI
- Zilbrysq (zilucoplan) MHI

Updated policies

- Infliximab and Biosimilars MHI
- Livmarli (maralixibant) MHI
- PCSK9 Inhibitors (alirocumab, evolocumab) MHI
- Promacta (eltrombopag) MHI
- Soliris (eculizumab), Ultomiris (ravulizumab) MHI
- Spevigo (spesolimab-sbzo) MHI
- Xolair (omalizumab) MHI

Policies changed from MHI to MCP

- Dextenza (dexamethasone intracanalicular ophthalmic insert) MCP
- Dexycu (Dexamethasone intraocular suspension) MCP
- Iluvien (fluocinolone acetonide intravitreal implant) MCP
- Retisert, Yutiq (fluocinolone acetonide intravitreal implants) MCP
- Susvimo (ranibizumab intravitreal injection implant) MCP

Evolent (NCH) policies

Molina Healthcare partners with Evolent (New Century Health) to administer cardiology and oncology services for members ages 18 and over. For clinical policies related to cardiology and oncology, please visit the [New Century Health website](#) or log into the [NCH provider portal](#).

- Abecma (idecabtagene vicleucel)
- Abraxane (nab paclitaxel)
- Adakveo (crizanlizumab)
- Adstiladrin (nadofaragene firadenovec-vncg)
- Alimta or Pemetrex (pemetrexed)
- Antiemetics
- Asparlas (calaspargase pegol-mknl)
- Balversa (erdafitinib)
- Beleodaq (belinosat)
- Blincyto (blinatumomab)
- Bone Modifying Agents (Aredia Zometa Xgeva Prolia)
- Breyanzi (lisocabtagene maraleucel)
- Caprelsa (vandetanib)
- Carvykti (ciltacabtagene autoleucel)
- Clolar (clofarabine)
- Cosela (trilaciclib)
- Criteria for Evidence Based Cancer Therapies
- Doxil (liposomal doxorubicin)
- Elahere (mirvetuximab soravtansine-gynx)
- Endari (l-glutamine)
- Enjaymo (sutimlimab-jome)
- Fotivda (tivozanib)
- Gavreto (pralsetinib)
- Gazyva (obinutuzumab)
- Generic Drugs

- Imlygic (Talimogene Laherparepvec)
- Iwifin (eflornithine)
- Jakafi (ruxolitinib)
- Kadcylla (ado-trastuzumab emtansine)
- Keytruda (pembrolizumab)
- Kimmtrak (tebentafusp-tebn)
- Krazati (adagrasib)
- Kymriah (tisagenlecleucel)
- Libtayo (cemiplimab-rwlc)
- Lorbreña (lorlatinib)
- Lunsumio (mosunetuzumab-axgb)
- Margenza (margetuximab-cmkb)
- Oncaspar (pegaspargase)
- Opdivo (nivolumab)
- Opdualag (nivolumab and relatlimab-rmbw)
- Orserdu (elacestrant)
- Photofrin (porfimer)
- Rezlidhia (olutasidenib)
- Rylaze (asparaginase Erwinia chrysanthemi recombinant-rywn)
- Sarclisa (isatuximab-irfc)
- Scemblix (asciminib)
- Somatostatin Analog
- Stivarga (regorafenib)
- Tagrisso (osimertinib)
- Tarceva (erlotinib)
- Tecartus (brexucabtagene autoleucel)
- Tepmetko (tepotinib)
- Tukysa (tucatinib)
- Venclexta (venetoclax)
- Votrient (pazopanib)
- Welireg (belzutifan)
- Xpovio (selinexor)
- Xtandi (enzalutamide)
- Yescarta (axicabtagene ciloleucel)
- Yondelis (trabectedin)
- Zaltrap (ziv-aflibercept)

- Zepzelca (lurbinectedin)
- Zevalin (ibritumomab tiuxetan)

Retired policy

- Relyvrio (sodium phenylbutyrate; sodium taurufsodiol) MHI

Molina clinical policies may be retired in favor of an existing MCG Guideline or other existing Molina clinical or pharmacy policy.

Questions?

We're here to help. Contact your dedicated Provider Relations Manager or email the Provider Network Management team at MHILProviderNetworkManagement@MolinaHealthcare.com. To help identify your dedicated Provider Relations Manager, visit [Molina's Service Area page](#) at MolinaHealthcare.com.

Provider portal alert

Providers no longer have direct access to the Molina Legacy Provider Portal. Ensure that you and your staff have access to streamlined claims management, authorizations, eligibility/benefit verification, and more. Get started with the [Avality Essentials Portal](#) today!

Get critical updates

Receive news and updates about Molina services and plan requirements delivered straight to your inbox! [Click here](#) to receive updates curated for Molina's Illinois providers.

Note: Molina's website and documents are best viewed in Google Chrome or Microsoft Edge.